Lialda - remission

When active, mild to moderate ulcerative colitis (UC) is the problem...
Lialda is approved to induce remission with once-daily dosing
Campaign files

Brand name: Lialda
Generic name/category: Mesalazine
Company: Shire
Country/Market: USA, North America
Indication(s)/Category: inflammation of the digestive tract in ulcerative colitis
Target: Healthcare Professionals (HCP)
Tagline: none
Medium: print ad
Size/duration: Single-page
Publication/Aired: GI and Hepatology News - October 2010

To see all of this brand's ads on AdPharm, [url=https://adpharm.net/thumbnails.php?search=Lialda"> Campaign files

From Wikipedia:

Mesalazine (INN, BAN), also known as Mesalamine (USAN) or 5-aminosalicylic acid (5-ASA), is an anti-inflammatory drug used to treat inflammation of the digestive tract ulcerative colitis and mild-to-moderate Crohn's disease. Mesalazine is a bowel-specific aminosalicylate drug that acts locally in the gut and has its predominant actions there, thereby having few systemic side effects. As a derivative of salicylic acid, 5-ASA is also thought to be an antioxidant that traps free radicals, which are potentially damaging byproducts of metabolism.

5-ASA is considered the active moiety of sulfasalazine, which is metabolized to it.

More on Wikipedia